Project Grant R01CA316827
Award Date 7/13/26
Completion Date 6/30/31
Dollars Obligated $724K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded New York University School of Medicine a $595,993 Project Grant (CFDA 93.395: Cancer Treatment Research) effective July 16, 2026, through July 31, 2031, to develop integrated biologic technologies for selective inhibition of intracellular oncoproteins. The project aims to establish a robust platform technology enabling direct and selective manipulation of intracellular driver oncoproteins and their interactions. The research...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $716,183 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective May 13, 2026, with a completion date of April 30, 2031. The award supports research to advance Chimeric Antigen Receptor (CAR) T-cell therapies by interrogating and targeting co-inhibitory and co-stimulatory molecules that limit current adoptive cell therapy effectiveness. The research...
- Federal Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded May 1, 2026, with completion targeted for April 30, 2031. This award funds fundamental research investigating T cell circuits within the lymphatic system during melanoma progression, with particular focus on tumor-draining lymph nodes (TDLNs) as immune surveillance hubs. The research aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a Project Grant totaling $257,472 (awarded September 6, 2025; completion date March 6, 2029) under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting the impact of genomic variants on T cell anti-tumor activity. The funded research addresses the critical challenge that while some patients with melanomas and leukemias respond durably to T...
- Summary of Federal Project Grant Award The University of Pittsburgh received a $379,644 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2028. The award funds research and development of cyclic peptide-based adaptors for universal Chimeric Antigen Receptor (CAR) T cell therapy. The project involves designing and synthesizing cyclic peptide adaptors to program SNAP-CAR T cells to recognize...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. This project focuses on the rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing a critical limitation in current chimeric antigen receptor (CAR) T cell treatments—limited...
- Federal Project Grant Award Summary New York University School of Medicine received a $169,500 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded July 3, 2026, with completion targeted for June 30, 2028. The award supports a computational research initiative to investigate the role of LINE-1 (L1) retrotransposons in human diseases by mining patient data from the NYU Langone database, which encompasses approximately 4.8 million...
- Federal Project Grant Award Summary Funding Agency & Program: The National Cancer Institute (NCI) awarded $399,829 under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, to Washington University's Office of Sponsored Research Services. Research Deliverables: This project grant funds mechanistic research and development of a novel dendritic cell (DC)-based cancer immunotherapy designated AB7H3-TLR4 CAR-DCs (Chimeric Antigen Receptor Dendritic Cells). The research...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Project Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The awardee will develop functional signatures of post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early prediction of patient response in relapsed/refractory large B cell lymphoma (R/RLBCL). The project leverages Cellchorus's proprietary Time-lapse...